COVID and erectile dysfunction are not automatically connected in every man who has had a respiratory infection. Most men recover without any persistent sexual symptoms, and erectile function is influenced by many variables, including age, vascular health, medications, sleep, anxiety, alcohol use, metabolic status, and relationship context. Still, a growing body of research suggests that SARS-CoV-2 infection may be associated with erectile dysfunction in some men, particularly when infection is followed by long-COVID symptoms, endothelial dysfunction, inflammatory stress, or hormonal disturbance.
COVID and Erectile Dysfunction: Why the Link Is Biologically Plausible
Erection is primarily a vascular event. Sexual stimulation triggers nitric oxide release, cyclic GMP signaling, cavernosal smooth muscle relaxation, arterial inflow, and temporary restriction of venous outflow. That sequence depends on healthy endothelial function, intact nerve signaling, adequate oxygen delivery, and normal hormonal support.
COVID-19 can affect several of those systems. SARS-CoV-2 uses the ACE2 receptor for cell entry, and ACE2 is expressed in vascular endothelium as well as other tissues relevant to male reproductive health. During acute infection, inflammation, oxidative stress, coagulation abnormalities, and endothelial injury may alter vascular responsiveness. In long COVID, persistent fatigue, dyspnea, sleep disturbance, mood symptoms, dysautonomia, reduced exercise capacity, and endocrine disruption may continue after the acute infection has resolved.
That does not mean COVID is a direct cause of ED in every case. Erectile dysfunction is common, especially after age 40, and many men already have underlying cardiovascular or metabolic risk factors before infection. The clinically useful question is narrower: can COVID reveal, worsen, or prolong mechanisms that already matter for erectile function? Current evidence suggests that it may.
What Population Studies Have Found
One of the larger U.S. analyses was published in the International Journal of Impotence Research. Kresch and colleagues used the IBM MarketScan claims database to compare men with and without prior COVID-19 infection. After adjustment, prior COVID-19 infection was associated with a higher risk of a new erectile dysfunction diagnosis, with a hazard ratio of 1.27 and a 95% confidence interval of 1.1 to 1.5 [1].
A later claims-database analysis by Gilliam and colleagues examined acute COVID, long COVID, hospitalization, and vasopressor exposure. After propensity-score matching, men with long COVID had a higher rate of new ED diagnosis or PDE5 inhibitor prescription than men with acute COVID alone: 3.63% versus 2.61%, corresponding to a relative risk of 1.39 [2]. Interestingly, hospitalization status and vasopressor use were not associated with a statistically significant increase in the measured endpoint. That finding suggests that persistent post-infection physiology may matter at least as much as acute severity in some patients.
These studies have limitations. Claims data depend on billing codes and prescriptions, not detailed symptom questionnaires. They may miss men who do not seek care, misclassify men who obtain treatment elsewhere, and cannot fully separate infection effects from pandemic-era stress, weight gain, reduced activity, medication changes, or delayed medical visits. Even so, large database studies are useful because they can detect patterns that smaller clinic series cannot.
Endothelial Dysfunction and Nitric Oxide Signaling
The most clinically coherent explanation is vascular. COVID-19 has been associated with endothelial dysfunction, microvascular injury, inflammatory activation, and altered coagulation. Erections are unusually sensitive to these changes because penile arteries are small and depend heavily on nitric oxide mediated vasodilation.
A healthy endothelial layer supports vasodilation by releasing nitric oxide. When endothelial function declines, nitric oxide bioavailability falls, oxidative stress rises, and smooth muscle relaxation becomes less reliable. This pathway overlaps with many established ED risk factors, including hypertension, diabetes, smoking, obesity, dyslipidemia, and physical inactivity.
COVID-related endothelial stress may therefore act as an additional vascular burden rather than an isolated, standalone cause. A man with excellent baseline vascular health may recover without noticing any change in sexual function. A man with central obesity, borderline blood pressure, insulin resistance, poor sleep, or low exercise capacity may have less physiologic reserve. In that context, infection and recovery can plausibly tip an already vulnerable system into symptomatic ED.
For men trying to understand the vascular context, the broader men's health library covers related topics such as blood pressure, cholesterol, metabolic syndrome, exercise, and nitric oxide signaling.
Testosterone, Inflammation, and the Hypothalamic-Pituitary-Gonadal Axis
Hormonal disruption is another plausible contributor. Testosterone is not the only determinant of erectile function, and many men with ED have normal testosterone levels. However, low testosterone may reduce libido, impair arousal, worsen fatigue, and make response to sexual stimulation less robust.
Al-kuraishy and colleagues studied men with erectile dysfunction three months after recovery from mild-to-moderate COVID-19 pneumonia and compared them with healthy controls. The long-COVID group had lower total testosterone, lower free testosterone, and lower free androgen index, along with altered luteinizing hormone patterns [3]. The authors interpreted the findings as potential evidence of hypothalamic-pituitary-gonadal axis dysfunction, while emphasizing the need for larger studies to clarify causality.
A systematic review and meta-analysis by Zhang and colleagues also reported that erectile dysfunction was more prevalent among COVID-19 patients and identified factors such as age, diabetes, and depression as relevant risk variables [4]. That matters clinically because testosterone, mood, sleep, and metabolic health often interact. A man recovering from infection may be less active, sleep worse, gain weight, experience depressive symptoms, and have lower libido. Any one of those factors can affect sexual function; together, they can be more disruptive.
Long COVID May Affect More Than Blood Flow
Long COVID is not a single symptom. It is a heterogeneous syndrome involving fatigue, exertional intolerance, sleep disturbance, cognitive symptoms, autonomic symptoms, mood changes, dyspnea, palpitations, pain, and reduced functional capacity. Several of those symptoms can indirectly impair sexual performance even when penile vascular function is not permanently damaged.
Fatigue can reduce desire and stamina. Breathlessness can make physical exertion feel more difficult. Poor sleep can suppress testosterone and increase sympathetic nervous system tone. Anxiety about relapse, heart rate, breathing, or performance can interfere with arousal. Depression can reduce libido and increase self-monitoring. Reduced exercise capacity can worsen endothelial function over time.
This is why post-COVID ED should not be evaluated as a purely urologic complaint in isolation. A clinician may need to consider cardiometabolic risk, blood pressure, glycemic status, lipid markers, medications, sleep apnea risk, mood symptoms, testosterone status, and the timeline of infection and recovery. The goal is not to assign blame to COVID. The goal is to identify which treatable mechanisms are present now.
When Men Should Seek Evaluation
A transient change in erection quality after illness, fever, stress, or sleep disruption is common and may improve as recovery progresses. Persistent erectile dysfunction is different. Men should consider medical evaluation when symptoms last more than several weeks, recur consistently, cause distress, or appear alongside reduced exercise tolerance, chest discomfort, shortness of breath, palpitations, new fatigue, low libido, depressed mood, or loss of morning erections.
The evaluation does not need to be excessive, but it should be medically grounded. Common considerations include blood pressure, waist circumference, fasting glucose or A1c, lipids, medication review, alcohol and nicotine use, sleep quality, symptoms of obstructive sleep apnea, testosterone testing when clinically indicated, and cardiovascular risk assessment. Because ED can precede overt cardiovascular disease, persistent new symptoms deserve attention rather than dismissal.
Treatment decisions should also be individualized. Some men benefit primarily from recovery time, sleep restoration, exercise progression, weight management, alcohol reduction, smoking cessation, or treatment of depression and anxiety. Others may be appropriate candidates for physician-supervised prescription therapy, especially when symptoms are recurrent and no contraindications exist. PDE5 inhibitors are not aphrodisiacs; they support the blood-flow pathway in response to sexual stimulation. They also require screening for nitrate use, cardiovascular status, medication interactions, and tolerability.
Conclusion
The current evidence does not prove that COVID directly causes erectile dysfunction in every affected man. It does suggest a clinically meaningful association, especially in the context of long COVID, vascular dysfunction, inflammatory stress, metabolic risk, and possible hormonal disruption. For men who notice persistent erection changes after COVID, the most useful response is not panic or self-diagnosis. It is a structured evaluation of the vascular, hormonal, neurologic, sleep, and psychological factors that determine erectile function.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including VAST, starting with a free online assessment at questionnaire.getonyxmd.com.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Kresch E, Achua J, Saltzman R, Khodamoradi K, Arora H, Ibrahim E, et al. Prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction. International Journal of Impotence Research. 2024;36:521-525. doi:10.1038/s41443-023-00687-4
- Gilliam K, Maremanda AP, Able C, Choi U, Alshak MN, et al. Comparing risk of post infection erectile dysfunction following SARS Coronavirus 2 stratified by acute and long COVID, hospitalization status, and vasopressor administration: a U.S. large claims database analysis. International Journal of Impotence Research. 2025;37:366-371. doi:10.1038/s41443-024-00913-7
- Al-kuraishy HM, Al-Gareeb AI, Alarfaj SJ, Al-Akeel RJ, Faidah H, El-Bouseary MM, et al. Long COVID and risk of erectile dysfunction in recovered patients from mild to moderate COVID-19. Scientific Reports. 2023;13:5977. doi:10.1038/s41598-023-32211-5
- Zhang J, Shi W, Zou M, Zeng Q, Feng Y, Luo Z, Gan H. Prevalence and risk factors of erectile dysfunction in COVID-19 patients: a systematic review and meta-analysis. Journal of Endocrinological Investigation. 2023;46(4):795-804. doi:10.1007/s40618-022-01945-w
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.